These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Nasu T; Kurisu S; Matsuno S; Tatsumi K; Kakimoto T; Kobayashi M; Nakano Y; Wakasaki H; Furuta H; Nishi M; Sasaki H; Suzuki H; Ito N; Fukumoto S; Nanjo K Intern Med; 2008; 47(10):957-61. PubMed ID: 18480582 [TBL] [Abstract][Full Text] [Related]
4. [Osteomalacia due to phosphate deficiency caused by a tumor. Focus on FGF23 in physiology and clinic]. Westerberg PA; Linde T; Ljunggren O Lakartidningen; 2012 Aug 8-21; 109(32-33):1414-6. PubMed ID: 22953430 [No Abstract] [Full Text] [Related]
5. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature. Mori Y; Ogasawara T; Motoi T; Shimizu Y; Chikazu D; Tamura K; Fukumoto S; Takato T Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):e57-63. PubMed ID: 20219587 [TBL] [Abstract][Full Text] [Related]
6. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia. Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220 [TBL] [Abstract][Full Text] [Related]
7. Effects of tumor-induced osteomalacia on the bone mineralization process. Nawrot-Wawrzyniak K; Varga F; Nader A; Roschger P; Sieghart S; Zwettler E; Roetzer KM; Lang S; Weinkamer R; Klaushofer K; Fratzl-Zelman N Calcif Tissue Int; 2009 Apr; 84(4):313-23. PubMed ID: 19219382 [TBL] [Abstract][Full Text] [Related]
9. [Chronic bone pain due to raised FGF23 production? The importance of determining phosphate levels]. de Jongh RT; Vervloet MG; Bravenboer N; Heijboer AC; den Heijer M; Lips P Ned Tijdschr Geneeskd; 2013; 157(28):A5908. PubMed ID: 23841927 [TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126 [TBL] [Abstract][Full Text] [Related]
11. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Bahrami A; Weiss SW; Montgomery E; Horvai AE; Jin L; Inwards CY; Folpe AL Am J Surg Pathol; 2009 Sep; 33(9):1348-54. PubMed ID: 19609206 [TBL] [Abstract][Full Text] [Related]
12. Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: cure after bilateral adrenalectomy. Ramon I; Kleynen P; Valsamis J; Body JJ; Karmali R Calcif Tissue Int; 2011 Dec; 89(6):442-5. PubMed ID: 21910004 [TBL] [Abstract][Full Text] [Related]
18. [Tumor-associated hypophosphatemic osteomalacia: case report and literature review]. Ewerbeck V; Simank HG; Krempien B Z Orthop Ihre Grenzgeb; 1994; 132(6):491-6. PubMed ID: 7831951 [TBL] [Abstract][Full Text] [Related]
19. Osteomalacia by a mesenchymal-FGF23-producing tumour: Successful treatment with radiofrequency ablation. A case report. Igney-Oertel A; Artunc F; Henes J; Hoffmann R; Clasen S Joint Bone Spine; 2016 Oct; 83(5):603-4. PubMed ID: 27006265 [No Abstract] [Full Text] [Related]